膀胱癌化疗耐药机制的研究进展  

Research progress on the mechanisms of chemoresistance in bladder cancer

作　　者：杨佳健 盖年鑫 林宇鑫 侯建全[1] 浦金贤[1] 赵晓俊[1] Yang Jiajian;Ge Nianxin;Lin Yuxin;Hou Jianquan;Pu Jinxian;Zhao Xiaojun(Department of Urology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院泌尿外科,215006

出　　处：《中华实验外科杂志》2022年第10期2046-2049,共4页Chinese Journal of Experimental Surgery

基　　金：江苏省重点研发计划(社会发展)项目-重点项目-临床前沿技术(BE2020655)。

摘　　要：膀胱癌具有高度的肿瘤异质性,目前,系统性铂基化疗仍是顺铂耐受膀胱癌患者治疗的一线选择。但多药耐药性、肿瘤干细胞、非编码RNA和活性氧等介导的化疗耐药仍然是导致膀胱癌患者疾病进展和预后不良的主要原因。因此,本文综述膀胱癌化疗耐药机制的最新研究进展,以期为膀胱癌的精准个性化治疗提供帮助。Bladder cancer(BCa)is observed with high tumor heterogeneity.Currently,systemic platinum-based chemotherapy is still the first-line choice for cisplatin-tolerated BCa patients.However,chemoresistance mediated by multidrug resistance,cancer stem cells,non-coding RNAs,reactive oxygen species and so on,remains a major cause leading to disease progression and poor prognosis in BCa patients.Hence,this paper reviews the recent research progress on the mechanisms of chemoresistance in BCa,which would be helpful for the precision and personalized therapy of BCa.

关 键 词：膀胱癌 化疗 耐药 

分 类 号：R737.14[医药卫生—肿瘤]